Literature DB >> 21843086

Cryptococcus neoformans galactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy.

Anna Vecchiarelli1, Eva Pericolini, Elena Gabrielli, Siu-Kei Chow, Francesco Bistoni, Elio Cenci, Arturo Casadevall.   

Abstract

Cryptococcus neoformans is an opportunistic fungal pathogen responsible for life-threatening infections in immunocompromised individuals and occasionally in those with no known immune impairment. The fungus is endowed with several virulence factors, including capsular polysaccharides that play a key role in virulence. The capsule is composed of 90-95% glucuronoxylomannan (GXM), 5-8% galactoxylomannan (GalXM) and <1% mannoproteins. Capsular polysaccharides are shed into tissue where they produce many deleterious effects. Since GalXM has a smaller molecular mass, the molar concentration of GalXM in polysaccharide that is shed could exceed that of GXM in C. neoformans exopolysaccharides. Moreover, GalXM exhibits a number of unusual biologic properties both in vitro and in vivo. Here, we summarize the principal immunomodulatory effects of GalXM described during the last 20 years, particularly the mechanisms leading to induction of apoptosis in T lymphocytes, B lymphocytes and macrophages. Since the capacity of GalXM to induce widespread immune suppression is believed to contribute to the virulence of C. neoformans, this property might be exploited therapeutically to dampen the aberrant activation of immune cells during autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21843086     DOI: 10.2217/imt.11.86

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  17 in total

Review 1.  Cryptococcus spp. and Cryptococcosis: focusing on the infection in Brazil.

Authors:  Fabíolla Nacimento do Carmo; Juliana de Camargo Fenley; Maíra Terra Garcia; Rodnei Dennis Rossoni; Juliana Campos Junqueira; Patrícia Pimentel de Barros; Liliana Scorzoni
Journal:  Braz J Microbiol       Date:  2022-04-29       Impact factor: 2.214

2.  Pbx proteins in Cryptococcus neoformans cell wall remodeling and capsule assembly.

Authors:  Pardeep Kumar; Christian Heiss; Felipe H Santiago-Tirado; Ian Black; Parastoo Azadi; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2014-02-28

Review 3.  Unraveling synthesis of the cryptococcal cell wall and capsule.

Authors:  Zhuo A Wang; Lucy X Li; Tamara L Doering
Journal:  Glycobiology       Date:  2018-10-01       Impact factor: 4.313

4.  Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models.

Authors:  Camaron R Hole; Floyd L Wormley
Journal:  Front Microbiol       Date:  2012-08-28       Impact factor: 5.640

5.  In good company: association between fungal glycans generates molecular complexes with unique functions.

Authors:  Marcio L Rodrigues; Leonardo Nimrichter
Journal:  Front Microbiol       Date:  2012-07-09       Impact factor: 5.640

Review 6.  Molecular mechanisms of cryptococcal meningitis.

Authors:  Tong-Bao Liu; David S Perlin; Chaoyang Xue
Journal:  Virulence       Date:  2012-03-01       Impact factor: 5.882

Review 7.  Cryptococcal pathogenic mechanisms: a dangerous trip from the environment to the brain.

Authors:  Shannon K Esher; Oscar Zaragoza; James Andrew Alspaugh
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-04-16       Impact factor: 2.743

8.  Pathogen-derived extracellular vesicles mediate virulence in the fatal human pathogen Cryptococcus gattii.

Authors:  Ewa Bielska; Marta Arch Sisquella; Maha Aldeieg; Charlotte Birch; Eloise J O'Donoghue; Robin C May
Journal:  Nat Commun       Date:  2018-04-19       Impact factor: 14.919

9.  The microbial capsular polysaccharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients.

Authors:  Eva Pericolini; Alessia Alunno; Elena Gabrielli; Elena Bartoloni; Elio Cenci; Siu-Kei Chow; Giovanni Bistoni; Arturo Casadevall; Roberto Gerli; Anna Vecchiarelli
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

10.  Phenotypic Variability Correlates with Clinical Outcome in Cryptococcus Isolates Obtained from Botswanan HIV/AIDS Patients.

Authors:  Kenya E Fernandes; Adam Brockway; Miriam Haverkamp; Christina A Cuomo; Floris van Ogtrop; John R Perfect; Dee A Carter
Journal:  mBio       Date:  2018-10-23       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.